Associated Papers
Nucleotide Substitution Biases in Related Cancer Driver Genes.
Khadre A et al.
International Journal of Molecular Sciences, 2025
A Phase I/II Trial of Ruxolitinib with Chemotherapy for Patients with Relapsed and/or Refractory Philadelphia-like Acute Lymphoblastic Leukemia.
Goulart H et al.
Clinical Lymphoma, Myeloma & Leukemia, 2025
Leveraging genomic diagnostics for prognostics and therapeutics in pediatric acute leukemia.
Newman H et al.
Hemasphere, 2025
Discriminating activating, deactivating and resistance variants in protein kinases.
Singh G et al.
Genome Medicine, 2025
Molecular landscape and clinical outcome of SRSF2/TET2 Co-mutated myeloid neoplasms.
Cockey SG et al.
Leukemia & Lymphoma, 2025
Insights into the role of JAK2-I724T variant in myeloproliferative neoplasms from a unique cohort of New Zealand patients.
Puli'uvea C et al.
Hematology (amsterdam, Netherlands), 2024
RNA-seq-based miRNA signature as an independent predictor of relapse in pediatric B-cell acute lymphoblastic leukemia.
Kubota H et al.
Blood Advances, 2024
Genetic background of thrombocytosis in mice mimicking hereditary thrombocytosis in humans.
Kimura H et al.
Platelets, 2023
A novel germline hyperactivating JAK2 mutation L604F.
Dvořáček L et al.
Annals of Hematology, 2023
Structural Analysis of Janus Tyrosine Kinase Variants in Hematological Malignancies: Implications for Drug Development and Opportunities for Novel Therapeutic Strategies.
Rodriguez Moncivais OJ et al.
International Journal of Molecular Sciences, 2023
Next-Generation JAK2 Inhibitors for the Treatment of Myeloproliferative Neoplasms: Lessons from Structure-Based Drug Discovery Approaches.
Nair PC et al.
Blood Cancer Discovery, 2023
JAK2 p.V617F Variants in Non-Blood DNA from Patients with Polycythemia Vera
Mori N et al.
Turkish Journal of Haematology : Official Journal of Turkish Society of Haematology, 2023
Clinical Characteristics and Outcomes of Patients with Primary and Secondary Myelofibrosis According to the Genomic Classification Using Targeted Next-Generation Sequencing.
Garrote M et al.
Cancers, 2023
Identification of putative noncanonical driver mutations in patients with essential thrombocythemia.
Arai A et al.
European Journal of Haematology, 2023
Characterization of myeloproliferative neoplasms in the paediatric and young adult population.
Harris Z et al.
British Journal of Haematology, 2023
Genetic basis and molecular profiling in myeloproliferative neoplasms.
Luque Paz D et al.
Blood, 2023
Deep genomic characterization highlights complexities and prognostic markers of pediatric acute myeloid leukemia.
Cheng CK et al.
Communications Biology, 2023
Recurrent germline variant in ATM associated with familial myeloproliferative neoplasms.
Braunstein EM et al.
Leukemia, 2023
The kinetics of blast clearance are associated with copy number alterations in childhood B-cell acute lymphoblastic leukemia.
Urbańska Z et al.
Neoplasia (new York, N.y.), 2023
Histological and genetic characterization and follow-up of 130 patients with chronic triple-negative thrombocytosis.
Lemoine S et al.
Haematologica, 2022
RaScALL: Rapid (Ra) screening (Sc) of RNA-seq data for prognostically significant genomic alterations in acute lymphoblastic leukaemia (ALL).
Rehn J et al.
Plos Genetics, 2022
Whole-transcriptome analysis in acute lymphoblastic leukemia: a report from the DFCI ALL Consortium Protocol 16-001.
Tran TH et al.
Blood Advances, 2022
Hereditary thrombocytosis: the genetic landscape.
Han EY et al.
British Journal of Haematology, 2021
Thrombocytosis in children and adolescents-classification, diagnostic approach, and clinical management.
Stockklausner C et al.
Annals of Hematology, 2021
Functional Consequences of Mutations in Myeloproliferative Neoplasms.
Constantinescu SN et al.
Hemasphere, 2021
New progress in the study of germline susceptibility genes of myeloid neoplasms.
Bi L et al.
Oncology Letters, 2021
Comprehensive Custom NGS Panel Validation for the Improvement of the Stratification of B-Acute Lymphoblastic Leukemia Patients.
Montaño A et al.
Journal of Personalized Medicine, 2020
Clinical utility of target capture-based panel sequencing in hematological malignancies: A multicenter feasibility study.
Yasuda T et al.
Cancer Science, 2020
A novel targeted RNA-Seq panel identifies a subset of adult patients with acute lymphoblastic leukemia with BCR-ABL1-like characteristics.
Sánchez R et al.
Blood Cancer Journal, 2020
Essential thrombocytosis attributed to JAK2-T875N germline mutation.
Yoshimitsu M et al.
International Journal of Hematology, 2019
Roles of T875N somatic mutation in the activity, structural stability of JAK2 and the transformation of OCI-AML3 cells.
Chen C et al.
International Journal of Biological Macromolecules, 2019
Differential effect of inhibitory strategies of the V617 mutant of JAK2 on cytokine receptor signaling.
Leroy E et al.
The Journal of Allergy and Clinical Immunology, 2019
Janus kinase 2 activation mechanisms revealed by analysis of suppressing mutations.
Hammarén HM et al.
The Journal of Allergy and Clinical Immunology, 2019
Surface expression of Cytokine Receptor-Like Factor 2 increases risk of relapse in pediatric acute lymphoblastic leukemia patients harboring IKZF1 deletions.
Pastorczak A et al.
Oncotarget, 2018
[Spectrum of somatic mutations and their prognostic significance in adult patients with B cell acute lymphoblastic leukemia].
Feng J et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi, 2018
Inhibition of mTORC1/C2 signaling improves anti-leukemia efficacy of JAK/STAT blockade in CRLF2 rearranged and/or JAK driven Philadelphia chromosome-like acute B-cell lymphoblastic leukemia.
Zhang Q et al.
Oncotarget, 2018
Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting.
He J et al.
Blood, 2016
Uncoupling JAK2 V617F activation from cytokine-induced signalling by modulation of JH2 αC helix.
Leroy E et al.
The Biochemical Journal, 2016
Rise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukaemia.
Ma X et al.
Nature Communications, 2015
JAK2 tyrosine kinase phosphorylates and is negatively regulated by centrosomal protein Ninein.
Jay J et al.
Molecular and Cellular Biology, 2015
Molecular basis for pseudokinase-dependent autoinhibition of JAK2 tyrosine kinase.
Shan Y et al.
Nature Structural & Molecular Biology, 2014
Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemia.
Mar BG et al.
Nature Communications, 2014